

State of the TB Alliance



Mel Spigelman, M.D.

TB Alliance Stakeholders Association Meeting

October 27, 2014

Barcelona, Spain



TB ALLIANCE

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT

SHA Meeting Agenda

Welcome and Introduction – *Karl Hofmann, SHA President*

State of the TB Alliance – *Mel Spigelman, President & CEO*

Research and Development Update – *Carl Mendel, SVP, Research & Development*

Highlights in Discovery – *Nader Fotouhi, Chief Scientific Officer*

Q&A

Market Access – *Elana Robertson, SVP, Market Access*

Q&A

Resource Mobilization and Advocacy – *Willo Brock, SVP, External Affairs*

Q&A

Message from Community Representative – *Mayowa Joel*

Message from the President – *Karl Hofmann*

Stakeholder discussion

Closing Comments - *Mel Spigelman*

Reception – *Café Veranda*

TB Alliance Vision

Current Treatment



6-30
Months

New Treatments in Development



2-4
Months


Aspirational Goal



7-10
Days

Success will require novel drug combinations

Current Therapy and Unmet Needs





Discovery

Early Development

Late Development

LEAD IDENTIFICATION	LEAD OPTIMIZATION	PRECLINICAL DEVELOPMENT	PHASE 1	PHASE 2A	PHASE 2B	PHASE 3	PHASE 4
ATP Synthesis Inhibitors <i>Calibr</i>	Macrolides <i>Sanofi</i>	TBA-354	Pharmacokinetics of first-line drugs in children < 5kg <i>Stellenbsch University</i>	NIX-TB PA-824 / Bedaquiline / Linezolid		Optimized Pediatric Formulations	Ethambutol/ Rifampicin/ Pyrazinamide for children > 5kg
Whole-Cell Hit-to-Lead Program <i>Sanofi</i>	Ureas <i>Sanofi</i>	Preclinical TB Regimen Development <i>JHU</i>					
Whole-Cell Hit-to-Lead Program <i>GSK</i>	Diarylquinolines <i>Janssen/University of Auckland/UIC</i>				NC-005 PA-824/ Bedaquiline/ Pyrazinamide	STAND PA-824/ Moxifloxacin/ Pyrazinamide	Isoniazid/ Rifampicin for children > 5kg
RNA Polymerase Inhibitors <i>Rutgers University</i>	Indazoles <i>GSK</i>						Ethambutol for children > 5kg
Energy Metabolism Inhibitors <i>AZ/Upenn</i>	Thiophene Carboxamides <i>Calibr</i>						Isoniazid for children > 5kg
POA Prodrugs <i>Yonsei</i>	Azaindoles <i>AZ</i>						Pyrazinamide for children > 5kg
InhA Inhibitors	Cyclopeptides <i>Sanofi</i>						
Hit ID Program <i>Takeda</i>	Mmpl3 Inhibitors						
Hit ID Program <i>Daiichi Sankyo</i>							
Hit ID Program <i>Shionogi</i>							

TB Alliance R&D Partners:

AstraZeneca (AZ)	New York Medical College
Bayer Healthcare AG (Bayer)	Rutgers University
Beijing Tuberculosis and Thoracic Tumor Research Institute	Sanofi
Calibr	Shionogi
Daiichi Sankyo	Stellenbosch University
GlaxoSmithKline (GSK)	Takeda Pharmaceuticals
Institute of Materia Medica (IMM)	University College London (UCL)
IMPAACT	University of Auckland
Janssen [Johnson & Johnson]	University of Illinois at Chicago (UIC)
Johns Hopkins University (JHU)	University of Pennsylvania School of Medicine
Medical Research Council (MRC)	Yonsei University

2014 – A Year of Accelerated Partnerships

- Market Access
 - Government agencies (NTPs, regulatory authorities, MOH,...)
 - WHO
 - NGOs – “on the ground” implementers
 - Manufacturers, distributors
- Research & Development
 - Enhanced clinical trial capacity (and decreased clinical trial costs)
 - Enhanced coordination – data and compound sharing, clinical trial planning
- Funding
 - Partnering along entire value chain
 - Greater involvement of middle income countries
 - “Consortia” funding of most expensive initiatives

TB Alliance Supporters

Thanks to all those who support our mission



UK aid



Bill & Melinda
Gates Foundation



UNITAID



United States Agency for
International Development



National Institute
of Allergy and
Infectious Diseases

National Institute of Allergy
and Infectious Diseases



AIDS Clinical
Trial Group



European
Commission



United States
Food and Drug
Administration



Global Health Innovative Technology Fund

Global Health Innovative
Technology Fund



Australian
Government



Irish Aid

Thank you!



TB ALLIANCE

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT